Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials

PURPOSE. The aim of this study was to investigate whether progression‐free survival (PFS) can be considered a surrogate endpoint for overall survival (OS) in malignant mesothelioma. MATERIALS AND METHODS. Individual data were collected from 15 Cancer and Leukemia Group B (615 patients) and 2 North C...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Wang, Xiaofei, Wang, Xiaoyi, Hodgson, Lydia, George, Stephen L., Sargent, Daniel J., Foster, Nate R., Ganti, Apar Kishor, Stinchcombe, Thomas E., Crawford, Jeffrey, Kratzke, Robert, Adjei, Alex A., Kindler, Hedy L., Vokes, Everett E., Pang, Herbert
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2017
Konular:
Lung Cancer
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5330706/
https://ncbi.nlm.nih.gov/pubmed/28188257
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0121
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller